ArticleMolecules (Basel, Switzerland)2026
Responses of Anti-Apoptotic Molecules to EAgNPs and EAgNPs Plus L-Buthionine-Sulfoximine in Human Tongue Cancer Cells.
Article in Molecules (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Silver nanoparticles (AgNPs) have emerged as a promising nanoplatform for oncological intervention, yet their clinical translation is severely hampered by systemic toxicities associated with high effective doses, while the underlying mechanisms governing their interactions with cancer cell pro-survival cascades remain poorly defined. In this study, we synthesized and fully characterized green tea polyphenol (-)-Epigallocatechin-3-gallate (EGCG)-derived silver nanoparticles (EAgNPs), in which EGCG acts as the reducing and capping agent. EAgNPs were confirmed to be highly dispersed, stable metallic silver particles with a primary size range of 4-7.6 nm. Subsequent mechanistic investigations performed on Tca8113 human tongue cancer cells revealed distinct dose-dependent anticancer action modes of EAgNPs: the 100 μM lethal dose effectively triggered robust apoptosis via potently suppressing the activity of key antioxidant selenoenzymes, including thioredoxin reductase and glutathione peroxidase (GPx), and multiple drug resistance proteins. Notably, even under this lethal treatment condition, Tca8113 cells still initiated theNrf2-associated antioxidant response characterized by 2-fold glutathione elevation and 25-fold heme oxygenase-1 upregulation. The 30 μM low-dose EAgNPs, however, failed to produce salient cytotoxicity, as they moderately inhibited GPx activity while comprehensively activating the integrated cancer cell defense network, including glutathione accumulation, Nrf2-associated antioxidant protein induction, and upregulation of a full panel of drug resistance proteins. Interestingly, the combination of 30 μM EAgNPs with the glutathione synthesis inhibitor L-buthionine-sulfoximine further enhanced selenoenzyme GPx inhibition and completely abrogated all above-mentioned inducible anti-apoptotic responses, resulting in multi-target disruption of the cytoprotective system and strongly enhanced apoptosis induction. Our findings demonstrate that this combinatorial strategy effectively lowers the therapeutic dose threshold of EAgNPs by disabling cancer cell adaptive resistance, providing a low-toxicity, translationally feasible approach for localized oral cancer treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.